2289 — Charmacy Pharmaceutical Co Income Statement
0.000.00%
- HK$928.80m
- HK$918.89m
- CNY4.40bn
- 13
- 78
- 40
- 36
Annual income statement for Charmacy Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | CAS | CAS | CAS | CAS | CAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,493 | 3,992 | 3,794 | 4,175 | 4,404 |
Cost of Revenue | |||||
Gross Profit | 213 | 230 | 225 | 259 | 279 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,438 | 3,940 | 3,761 | 4,054 | 4,337 |
Operating Profit | 54.4 | 51.8 | 32.4 | 122 | 66.2 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 55 | 54.7 | 33 | 122 | 67.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | 40.2 | 40.6 | 23.2 | 90.5 | 51.3 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 40.2 | 40.6 | 23.2 | 90.5 | 51.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 40.2 | 40.6 | 23.2 | 90.5 | 51.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.372 | 0.375 | 0.213 | 0.386 | 0.475 |
Dividends per Share |